RichardAlanLafayetteMD
Nephrology • Palo Alto, CAProfessor, Medicine - Nephrology, Stanford University Medical Center
Dr. Lafayette is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Pasteur Dr
Palo Alto, CA 94305Phone+1 650-725-6186Fax+1 650-725-8418- Is this information wrong?
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Nephrology, 1988 - 1991
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1985 - 1987
New York Medical CollegeClass of 1985
Certifications & Licensure
CA State Medical License 1988 - 2025
MA State Medical License 1992 - 1996- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM) Start of enrollment: 2005 Jun 01
- Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Start of enrollment: 2009 Feb 01
- MEmbranous Nephropathy Trial Of Rituximab Start of enrollment: 2011 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Longitudinal analysis of blood pressure and lipids in childhood nephrotic syndrome.Carboni, J., Thomas, E., Gipson, D., Brady, T., Srivastava, T., Selewski, D., Greenbaum, L., Wang, C., Dell, K., Kaskel, F., Massengill, S., Reidy, K., Tran, C., Trach...> ;Pediatric Nephrology. 2024 Feb 6
- Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy.Tam, F., Tumlin, J., Barratt, J., Rovin, B., Roberts, I., Roufosse, C., Cook, H., Bhangal, G., Brown, A., Busch, M., Dudhiya, F., Duliege, A., Fraser, D., Gale, D., Hu...> ;Kidney International Reports. 2023 Dec 1
- 7 citationsEfficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.Brad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, Charles E Alpers, Stewart Bieler, Dong-Wan Chae, Ulysses A Diva, Jürgen Floege, Loreto Gesualdo, Jula K Inrig, Don...> ;Lancet. 2023 Dec 2
- Join now to see all
Journal Articles
- Cause of Kidney Disease and Cardiovascular Events in a National Cohort of US Patients with End-Stage Renal Disease on Dialysis: A Retrospective AnalysisWolfgang C Winkelmayer, Richard A Lafayette, European Heart Journal
Abstracts/Posters
- Facing the Vexing Problem of Recurrent FSGS After Kidney TransplantationRichard Lafayette, MD, American Society of Nephrology, Orlando, FL, 12/7/2019
- Facing the Vexing Problem of Recurrent FSGS After Kidney TransplantationRichard Lafayette, MD, American Society of Nephrology, Orlando, FL, 12/7/2019
Press Mentions
Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023May 5th, 2023- Omeros Announces Results from Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy TrialNovember 5th, 2021
- Vera Therapeutics Hosting Key Opinion Leader Webinar on IgA NephropathySeptember 9th, 2021
- Join now to see all
Grant Support
- Oral Calcimimetic Agent In Secondary HyperparathyroidismNational Center For Research Resources2000–2001
Hospital Affiliations
Lucile Packard Children's Hospital StanfordPalo Alto, California
Stanford Health CarePalo Alto, California
Mills-Peninsula Medical CenterBurlingame, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
